Dunphy K, Bazou D, Henry M, Meleady P, Miettinen J, Heckman C
Cancers (Basel). 2023; 15(15).
PMID: 37568580
PMC: 10417544.
DOI: 10.3390/cancers15153764.
Zhang Q, Yang Y, You X, Ju Y, Zhang Q, Sun T
Front Oncol. 2023; 13:1173275.
PMID: 37546405
PMC: 10401477.
DOI: 10.3389/fonc.2023.1173275.
Giannoni P, de Totero D
Cancer Drug Resist. 2022; 4(4):923-933.
PMID: 35582373
PMC: 8992445.
DOI: 10.20517/cdr.2021.73.
Baljevic M, Zaman S, Baladandayuthapani V, Lin Y, de Partovi C, Berkova Z
Ann Hematol. 2017; 96(6):977-985.
PMID: 28337527
PMC: 5406425.
DOI: 10.1007/s00277-017-2980-3.
Lendvai N, Yee A, Tsakos I, Alexander A, Devlin S, Hassoun H
Blood. 2016; 127(19):2355-6.
PMID: 27020089
PMC: 5003505.
DOI: 10.1182/blood-2016-01-694786.
Satellite cells in human skeletal muscle plasticity.
Snijders T, Nederveen J, McKay B, Joanisse S, Verdijk L, van Loon L
Front Physiol. 2015; 6:283.
PMID: 26557092
PMC: 4617172.
DOI: 10.3389/fphys.2015.00283.
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.
de la Puente P, Muz B, Gilson R, Azab F, Luderer M, King J
Biomaterials. 2015; 73:70-84.
PMID: 26402156
PMC: 4917006.
DOI: 10.1016/j.biomaterials.2015.09.017.
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.
Tian E, Borset M, Sawyer J, Brede G, Vatsveen T, Hov H
Genes Chromosomes Cancer. 2015; 54(11):692-701.
PMID: 26220195
PMC: 5644988.
DOI: 10.1002/gcc.22280.
Novel Role for γ-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1).
Sechler M, Borowicz S, Van Scoyk M, Avasarala S, Zerayesus S, Edwards M
J Biol Chem. 2015; 290(25):15610-15620.
PMID: 25925948
PMC: 4505473.
DOI: 10.1074/jbc.M114.631820.
Mechanisms of hepatocyte growth factor activation in cancer tissues.
Kawaguchi M, Kataoka H
Cancers (Basel). 2014; 6(4):1890-904.
PMID: 25268161
PMC: 4276949.
DOI: 10.3390/cancers6041890.
Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.
Roversi F, Lopes M, Machado-Neto J, Longhini A, Duarte A, Baratti M
Stem Cells Dev. 2014; 23(10):1109-20.
PMID: 24410667
PMC: 4015506.
DOI: 10.1089/scd.2013.0441.
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Chou F, Chen Y, Zhao X, Xu-Monette Z, Young K, Gartenhaus R
Am J Pathol. 2013; 183(4):1306-17.
PMID: 24070417
PMC: 3791685.
DOI: 10.1016/j.ajpath.2013.06.024.
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.
Bonanno G, Mariotti A, Procoli A, Folgiero V, Natale D, de Rosa L
J Transl Med. 2012; 10:247.
PMID: 23232072
PMC: 3543251.
DOI: 10.1186/1479-5876-10-247.
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
Rutella S, Locatelli F
Clin Dev Immunol. 2012; 2012:196063.
PMID: 22567028
PMC: 3332181.
DOI: 10.1155/2012/196063.
Hepatocyte growth factor system in the mouse uterus: variation across the estrous cycle and regulation by 17-beta-estradiol and progesterone.
Zhang X
Biol Reprod. 2010; 82(6):1037-48.
PMID: 20147731
PMC: 2874493.
DOI: 10.1095/biolreprod.109.079772.
Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.
Wader K, Fagerli U, Holt R, Stordal B, Borset M, Sundan A
Eur J Haematol. 2008; 81(5):380-3.
PMID: 18691255
PMC: 2659365.
DOI: 10.1111/j.1600-0609.2008.01130.x.
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kandefer-Szerszen M
Arch Immunol Ther Exp (Warsz). 2008; 56(3):207-21.
PMID: 18512025
PMC: 2766495.
DOI: 10.1007/s00005-008-0022-5.
Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer.
Kitajima Y, Ide T, Ohtsuka T, Miyazaki K
Cancer Sci. 2008; 99(7):1341-7.
PMID: 18422749
PMC: 11159873.
DOI: 10.1111/j.1349-7006.2008.00828.x.
Structural insight into distinct mechanisms of protease inhibition by antibodies.
Wu Y, Eigenbrot C, Liang W, Stawicki S, Shia S, Fan B
Proc Natl Acad Sci U S A. 2007; 104(50):19784-9.
PMID: 18077410
PMC: 2148376.
DOI: 10.1073/pnas.0708251104.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y
Cancer Sci. 2007; 98(4):491-8.
PMID: 17309599
PMC: 11160002.
DOI: 10.1111/j.1349-7006.2007.00412.x.